Tradjenta can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes -metformin, sulfonylurea or pioglitazone.
In a study, the drug showed reduction in hemoglobin A1C (HbA1C or A1C) levels up to 0.7% (compared to placebo).
When used in combination with metformin, sulfonylurea, and metformin plus sulfonylurea, the addition of Tradjenta resulted in A1C reductions of 0.6, 0.5, and 0.6% respectively (compared to placebo).
Lilly Diabetes president Enrique Conterno said Tradjenta is the first regulatory approval of what they hope will be many new treatment options this alliance brings to the millions of Americans living with type 2 diabetes.
In January 2011, Boehringer Ingelheim and Eli Lilly had forged alliance in the field of diabetes that centers on four pipeline compounds representing several of the largest treatment classes.